Hemispherx Announces Primate Research Showing Alferon(R) LDO Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
September 22, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Protection from...
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Agree to Collaborate in Studying Alferon(R) and Ampligen(R) Against the Ebola Virus
September 08, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that the Company and USAMRIID scientists have agreed to test...
Hemispherx's Two Drugs, Ampligen(R) and Alferon(R) Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses
August 04, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a peer-reviewed electronic publication entitled "Sensitivity of SARS/MERS CoV to Interferons and...
Hemispherx Biopharma and Bioclones, a Leading South African Biotechnology Company, Join Forces on Novel Therapeutic Cancer Vaccine
July 14, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, July 14, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced a strategic alliance to develop multiple projects with Bioclones...
Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate in Middle Eastern Respiratory Syndrome (MERS)
June 16, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 16, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced that a new publication (June 2, 2014) in the Formulary Journal...
Hemispherx Announces That the University of Texas Medical Branch Confirms Activity of Alferon(R) N Against MERS (Middle East Respiratory Syndrome) Virus
June 03, 2014 13:06 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has confirmed that one of its advanced stage biological products, Alferon® N, inhibits...
Hemispherx Biopharma Formally Collaborates With the Swiss Department of Defense, Civil Protection and Sports to Study Alferon(R) Against Tamiflu Resistant Influenza Virus Strains
May 14, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 14, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it has entered into a formal collaborative research agreement...
A Clinical Update on the Search for a Universal Flu Vaccine: Presentation in Washington, DC on January 30, 2014 in Conjunction With the American Society for Microbiology (ASM) Biodefense Conference
January 28, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that the ASM Biodefense Meeting is scheduled for January 27-29, 2014 at the Washington Marriott...
Hemispherx Analysis of New Data on Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
January 22, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced that Dr. William M. Mitchell of Vanderbilt University presented a research paper on January 21,...
Hemispherx Biopharma Reports Evidence Based Clinical Potential of a Natural Interferon (IFN) -- Alpha for Infection Control and Treatment of Drug Resistant H7N9 Influenza Virus
January 07, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced publication of an article entitled "Emergence of a novel drug...